How to Remove Thyroid Nodules: Surgery & Non-Surgical Options

Thyroid nodules can be removed through conventional surgery, minimally invasive surgical techniques, or nonsurgical thermal and chemical ablation, and the best option depends on whether the nodule is benign or malignant, how large it is, and what symptoms it causes. Most thyroid nodules never need removal at all. But when treatment is warranted, the landscape has expanded well beyond the traditional choice of having your thyroid partially or fully cut out. Radiofrequency ablation, microwave ablation, ethanol injection, and even focused ultrasound now offer alternatives that preserve thyroid tissue and avoid a visible scar, though each comes with trade-offs worth understanding before you commit.

When a Thyroid Nodule Actually Needs Treatment

Roughly half of all adults will have at least one thyroid nodule if you look with ultrasound, but only a small fraction of those nodules require any intervention. The reasons to treat fall into three buckets: the nodule is cancerous or suspicious for cancer, the nodule is large enough to cause compressive symptoms like difficulty swallowing or a visible lump, or the nodule is an autonomously functioning “hot” nodule causing hyperthyroidism. If your nodule is small, benign on biopsy, and not bothering you, the standard recommendation is periodic ultrasound monitoring and nothing more.

The first step in deciding whether a nodule needs treatment is ultrasound-based risk stratification. Several scoring systems exist globally, and a network meta-analysis of 39 studies covering nearly 50,000 patients found that at their highest-suspicion thresholds, these systems generally achieve sensitivities of about 64–77% and specificities of 82–90% for detecting cancer.¹ In practical terms, ultrasound alone can flag worrisome nodules reliably, but it is not definitive. That is why suspicious-looking nodules get a fine-needle aspiration biopsy.

Biopsy results are reported using the Bethesda system, a six-tier classification that ranges from nondiagnostic samples all the way to frankly malignant cells. In a large surgical series of over 1,200 patients, the actual malignancy rate on final pathology was 11% for nodules called benign on biopsy, 84% for those called suspicious for malignancy, and 98% for those called outright malignant.² Nodules in the middle categories, sometimes labeled “indeterminate,” present a trickier decision.

The Role of Molecular Testing for Indeterminate Nodules

About one in five thyroid biopsies comes back indeterminate, meaning the cells look neither clearly benign nor clearly malignant.³ Historically, many of these patients were sent to surgery just to get a definitive diagnosis, only to learn afterward that the nodule was benign. This is where molecular testing has changed the game. Tests like Afirma GSC and ThyroSeq v3 analyze gene expression or mutations in the biopsy sample to refine the risk estimate.

A systematic review and meta-analysis found that molecular testing avoids unnecessary surgery in roughly 50–69% of indeterminate nodule cases.⁴ A follow-up study tracking indeterminate nodules with benign molecular results over three years of nonsurgical management found that the vast majority remained stable, with only one missed cancer identified, supporting the reliability of these tests in ruling out malignancy.⁵ That said, malignancy rates for indeterminate nodules vary by practice setting. Data from a comprehensive cancer center found that 27–38% of one indeterminate category harbored cancer, higher than older estimates suggested.⁶ So context matters: the same biopsy result at a general community hospital and at a cancer referral center may carry different real-world risks.

Conventional Thyroid Surgery

When surgery is needed, the two standard operations are lobectomy (removing one lobe) and total thyroidectomy (removing the entire gland). Lobectomy is generally preferred for benign nodules confined to one side, for small low-risk cancers, and for diagnostic purposes when the preoperative workup cannot settle the question of malignancy. A study following lobectomy patients for benign unilateral nodules found a low rate of nodular relapse, particularly when the opposite lobe was normal in size beforehand.⁷

Total thyroidectomy is reserved for larger or bilateral cancers, multinodular goiters affecting both lobes, Graves’ disease, and situations where complete removal simplifies radioactive iodine treatment afterward. The trade-off is straightforward: removing the entire gland means you will need lifelong thyroid hormone replacement. After lobectomy, most patients retain enough thyroid function to stay off medication. In one large series, only about 14% of lobectomy patients needed thyroid hormone replacement, though the rate climbed to over 40% among those who had higher baseline TSH levels before surgery.⁸

Both operations carry risks of recurrent laryngeal nerve injury, which can affect voice quality, and hypoparathyroidism, which disrupts calcium regulation. In a study of over 340 thyroid surgeries, transient vocal cord problems occurred in about 3% of cases, with permanent injury in under 1%.⁹ The risk was substantially higher in reoperation and in surgery for malignant disease. Hypoparathyroidism risk similarly increases with the extent of surgery: total thyroidectomy, neck dissection, and incidental removal of parathyroid glands during the procedure all raise the odds.¹⁰

Scarless and Robotic Surgical Approaches

For patients who want surgery but are concerned about a visible neck scar, several remote-access techniques have emerged. The most studied is the transoral endoscopic thyroidectomy vestibular approach, or TOETVA, in which instruments enter through small incisions inside the lower lip. A meta-analysis comparing TOETVA with open thyroidectomy found similar safety profiles, with no significant differences in nerve injury, calcium problems, or blood loss. TOETVA did involve less postoperative pain but longer operating times and hospital stays.¹¹

A more recent propensity-matched study found that TOETVA was associated with fewer inadvertently removed parathyroid glands compared to open surgery, but it came with higher costs (averaging about $4,700 versus $2,700) and a greater chance of specimen disruption, meaning the tissue sample was more likely to be fragmented during removal.¹² Specimen disruption matters mainly for cancer cases, where pathologists need an intact specimen to assess margins.

Robotic thyroidectomy, which typically uses the da Vinci system through incisions hidden in the armpit or behind the ear, is another option. A meta-analysis found it to be as safe and effective as conventional open surgery, with better cosmetic satisfaction scores.¹³ The bilateral axillo-breast approach, which routes instruments through both armpits and the chest, showed good surgical completeness in a series of over 1,000 patients.¹⁴ These remote-access techniques are best suited for small to moderately sized thyroid glands. They are not practical for very large goiters or locally advanced cancers.

Radiofrequency Ablation

Radiofrequency ablation, or RFA, has become the most widely studied nonsurgical treatment for benign thyroid nodules. A needle-like electrode is inserted into the nodule under ultrasound guidance, and heat destroys the tissue from the inside. The dead tissue gradually shrinks over the following months as the body reabsorbs it.

A large prospective multicenter study followed 276 nodules after RFA and reported average volume reductions of about 80% at one year, increasing to roughly 95% at five years. The therapeutic success rate was nearly 98%, and major complications occurred in only 1% of patients.¹⁵ Another study similarly found volume reductions of about 66% at six months and 74% at one year with no complications.¹⁶ In a U.S. trial tracking a learning curve among operators new to the technique, the median volume reduction reached about 71% at 12 months, with minor complications in about 5% of cases and no major ones.¹⁷

A key advantage of RFA over surgery is thyroid function preservation. A study of patients who had already undergone lobectomy on one side and then developed new benign nodules in the remaining lobe found that thyroid hormone levels remained stable after RFA, avoiding the total thyroidectomy that would otherwise have been necessary.¹⁸ Vocal cord issues can still occur with RFA, though they tend to be mild and transient. One study using real-time laryngeal ultrasound during the procedure detected transient vocal cord palsy in about 4% of patients, with all cases recovering within a week.¹⁹

Microwave Ablation

Microwave ablation works on a similar principle to RFA but uses a different energy source to generate heat. It can reach higher temperatures more quickly, and some practitioners find it faster for large nodules. In head-to-head comparisons, the two techniques perform comparably. A systematic review and meta-analysis found similar volume reduction rates at three and six months, though RFA showed a slightly higher reduction at 12 months (about 86% versus 80%). Complication rates did not differ significantly between the two.²⁰

A randomized controlled trial comparing the two techniques for predominantly solid benign nodules found that microwave ablation was noninferior to RFA in volume reduction at both six months and two years, with comparable efficacy rates of about 91% for microwave versus 86% for RFA.²¹ From a patient’s perspective, the experience is similar for both: an outpatient procedure under local anesthesia, with most people returning to normal activities within a day or two.

Ethanol Ablation for Cystic Nodules

Not all thyroid nodules are solid. Some are filled with fluid (cystic), and others are a mix of solid and fluid (predominantly cystic). For these fluid-containing nodules, ethanol ablation is often the first-line nonsurgical treatment. The technique involves draining the cyst fluid and injecting medical-grade ethanol, which destroys the cyst lining and reduces the chance of the fluid reaccumulating.

A systematic review and meta-analysis confirmed ethanol ablation’s role as first-line therapy for benign thyroid cysts and predominantly cystic nodules, finding it highly effective with a good safety profile compared to other nonsurgical options.²² Individual studies have reported volume reductions averaging about 85%, with therapeutic success rates around 90%.²³ Purely cystic nodules respond better than predominantly cystic ones, since the solid component is harder for ethanol to destroy. Two techniques exist: retaining the ethanol inside the cyst versus aspirating it back out after a dwell period. One study found equivalent volume reduction with both methods, though the retention technique caused more post-procedure pain.²⁴

Ethanol ablation is cheap, widely available, and does not require specialized equipment beyond an ultrasound machine and a needle. Its main limitation is that it does not work well for solid nodules, which is where RFA or microwave ablation takes over.

High-Intensity Focused Ultrasound

High-intensity focused ultrasound, or HIFU, stands apart from the other ablation methods because it does not require any needle insertion at all. It works by focusing ultrasound waves from outside the neck to generate heat at a precise point inside the nodule. This makes it the only truly noninvasive option.²⁵

The trade-off is efficacy. Early clinical data showed a mean volume reduction of about 49% at six months, lower than what RFA typically achieves.²⁶ A two-year follow-up study found that volume reduction continued gradually, reaching about 70% at 24 months, but also noted that roughly one in five nodules had regrown beyond 12 months, suggesting longer surveillance is necessary.²⁷ Smaller nodules responded better, and highly vascular nodules responded worse. HIFU remains more widely available in Europe and Asia than in North America, and the evidence base is thinner than for RFA. It may suit patients who are anxious about needles or who have small, cosmetically bothersome nodules where a moderate volume reduction would be adequate.

Ablation Versus Surgery for Quality of Life

When patients have a choice between thermal ablation and surgery for benign nodules, the quality-of-life data generally favors ablation in the short to medium term. A randomized trial comparing thermal ablation with conventional thyroidectomy found that at 15 months, more ablation patients were satisfied with their treatment and scored higher on quality-of-life measures. The ablation group also had shorter hospital stays, though the volume reduction took longer to reach its maximum compared to surgical excision, which removes the nodule immediately.²⁸

A systematic review comparing thermal ablation with conventional thyroidectomy found lower rates of hoarseness, hypothyroidism, and postoperative pain in the ablation group, along with shorter hospitalization and better cosmetic outcomes.²⁹ A propensity-matched study tracking patient-reported outcomes for two years after treatment of low-risk thyroid cancer found that thermal ablation was associated with fewer head and neck symptoms, fewer voice and swallowing problems, and less body-image concern than open surgery at six, 12, and 24 months.³⁰

One wrinkle: when ablation is compared not with open surgery but with scarless endoscopic thyroidectomy (TOETVA), the cosmetic advantage flips. A propensity-matched comparison found that TOETVA patients reported better cosmetic results and higher overall satisfaction than RFA patients at one year, since complete surgical removal eliminates the nodule entirely while ablation leaves a slowly shrinking remnant.³¹ So if your primary concern is cosmetic appearance and the nodule is an appropriate surgical candidate, scarless surgery may outperform ablation on the metric that matters most to you.

Regrowth After Ablation and the Long Game

Ablation shrinks a nodule rather than removing it, so there is always some risk that the surviving rim of tissue grows back. One follow-up study tracking patients for up to seven years after a single session of RFA found that regrowth occurred in about 24% of cases, typically around three years after the procedure.³² Ten-year data from a separate cohort pegged the regrowth rate at about 12%, with the majority of those patients managed by a repeat ablation session rather than being sent to surgery.³³ Larger nodules (over 20 mL in initial volume) were more prone to regrowth than smaller ones.

When re-treatment is needed, a multicenter study from Italy found that ablation re-treatment had a technique inefficacy rate of about 52%, with a secondary regrowth rate of roughly 13%.³⁴ This suggests that a subset of nodules are stubborn enough that ablation eventually reaches its limits, and surgery becomes the more practical path. This is an important consideration when you are weighing the initial choice: ablation buys you a less invasive first step, but for very large or recurrent nodules, you may eventually face the operating room anyway.

Cost Differences

In most health economic analyses, RFA comes out ahead of surgery for benign nodules. A cost-effectiveness model found that RFA yielded slightly more quality-adjusted life years at a lower total cost compared to lobectomy (about $16,600 versus $19,300), making it the dominant strategy. RFA remained cost-effective unless the procedure cost exceeded roughly $12,000–$18,000 per session depending on the willingness-to-pay threshold used.³⁵ A separate prospective analysis in a different health system found that RFA cost about 76% of what a partial thyroidectomy cost.³⁶

These figures are sensitive to local pricing, insurance coverage, and whether re-treatment is eventually needed. In countries where RFA is not yet widely covered by insurance, out-of-pocket costs can be high enough to shift the calculus. And as noted above, if a nodule regrows and needs a second session, the cumulative cost advantage narrows.

Active Surveillance for Small Low-Risk Cancers

Not every thyroid cancer needs immediate treatment. Papillary thyroid microcarcinomas, which are cancers smaller than one centimeter, are often so slow-growing that active surveillance has become a recognized alternative to surgery. The idea is the same as “watchful waiting” used for some prostate cancers: monitor the tumor with regular ultrasound, and only intervene if it grows or shows signs of progression.³⁷

An Italian single-center study following 93 patients with papillary microcarcinomas under active surveillance found that only 3% showed clinical progression requiring surgery over a median follow-up of about 19 months. Another 20% elected surgery for personal reasons rather than medical necessity, and all operated patients had excellent outcomes despite the delay.³⁸ Active surveillance is not appropriate for all thyroid cancers. It requires specific criteria: the cancer must be small, confined to the thyroid, not near the trachea or recurrent laryngeal nerve, and the patient must be willing to commit to regular monitoring visits.

Substernal Goiters and Other Complicated Anatomy

A substernal goiter is a thyroid enlargement that extends down behind the breastbone into the chest. These are almost always treated surgically because their size and position make ablation impractical, and they can compress the airway or major blood vessels. The good news is that the vast majority can be removed through a standard neck incision without opening the chest. A meta-analysis of substernal goiter surgery found that a cervical approach alone was used in about 89% of cases, while roughly 10% required an additional thoracic procedure such as a sternotomy.³⁹

Substernal goiter surgery carries somewhat higher complication rates than standard thyroidectomy. A retrospective review of over 2,100 patients found that transient hypoparathyroidism occurred in 15% and permanent recurrent laryngeal nerve injury in about 4%, with the thoracic approach carrying significantly higher risk of nerve injury than the cervical-only route.⁴⁰ If you have been told you have a substernal goiter, choosing an experienced, high-volume thyroid surgeon matters even more than usual. Expert endocrine surgeons report needing to go beyond a cervical approach only about 2% of the time.⁴¹

How the Decision Gets Made

The variation in treatment choices is not driven entirely by the nodule itself. A multi-institutional Canadian study looking at decision-making for indeterminate thyroid nodules found that over 11% of the variability in whether patients had surgery could be explained by differences between surgeons rather than differences between patients.⁴² Your surgeon’s comfort level, institutional norms, and the availability of molecular testing and ablation technology all influence what options are presented to you.

This means it is reasonable to seek a second opinion, especially if you have been told you need surgery for a benign or indeterminate nodule and you are interested in ablation, or vice versa. The field is evolving quickly enough that not every practice has adopted the newer technologies, and different specialists bring genuinely different expertise. An endocrinologist, an interventional radiologist, and a thyroid surgeon may each see your nodule through the lens of their own training and the tools available to them. The best outcomes tend to follow when patients understand the full menu of options and participate actively in the choice.